SCHEMBL4532026

SCHEMBL4532026

NC(=S)Nc1cccnc1F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.60
CYP3A4 P08684 2/20 0.60
L3MBTL1 Q9Y468 4/20 0.50
MAPT P10636 4/20 0.50
ALDH1A1 P00352 4/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
NPSR1 Q6W5P4 1/20 0.45
GLA P06280 1/20 0.41
KDM4E B2RXH2 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 1/20 0.41
RRM2 P31350 1/20 0.41
NCOA1 Q15788 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
RAB9A P51151 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19808607 0.79 CYP1A2 (0.62) CYP1A2CYP3A4L3MBTL1MAPTALDH1A1
SCHEMBL4509925 0.78 CYP1A2 (0.60) CYP1A2CYP3A4L3MBTL1MAPTALDH1A1
SCHEMBL4512999 0.75 CYP1A2 (1.00) CYP1A2CYP3A4L3MBTL1MAPTALDH1A1
SCHEMBL25043753 0.74 MEN1 (0.58) CYP1A2CYP3A4ALDH1A1MEN1KMT2A
SCHEMBL476469 0.74
SCHEMBL4058238 0.74 CYP1A2 (0.55) CYP1A2CYP3A4L3MBTL1MAPTALDH1A1
SCHEMBL29653970 0.74 MEN1 (0.62) CYP1A2CYP3A4L3MBTL1MAPTALDH1A1
SCHEMBL4511393 0.74 MEN1 (0.62) CYP1A2CYP3A4L3MBTL1MAPTALDH1A1
SCHEMBL7593748 0.73 L3MBTL1 (0.71) CYP1A2CYP3A4L3MBTL1MAPTALDH1A1
SCHEMBL29639347 0.72 L3MBTL1 (0.59) L3MBTL1MAPTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9150561-B2 Thiazole derivatives and use thereof MERCK SERONO S.A. (CH) 2015-10-06 US disclosed
US-20140228365-A1 THIAZOLE DERIVATIVES AND USE THEREOF MERCK SERONO S.A. (CH) 2014-08-14 US disclosed
US-8802861-B2 Thiazole derivatives and use thereof MERCK SERONO SA (CH) 2014-08-12 US disclosed
US-20090029998-A1 Thiazole Derivatives and Use Thereof APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) 2009-01-29 US disclosed
EP-1709019-B1 THIAZOLE DERIVATIVES AND USE THEREOF APPLIED RESEARCH SYSTEMS (AN) 2007-08-08 EP disclosed
EP-1709019-A2 THIAZOLE DERIVATIVES AND USE THEREOF Applied Research Systems ARS Holding N.V. (AN) 2006-10-11 EP disclosed
WO-2005068444-A2 THIAZOLE DERIVATIVES AND USE THEREOF APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2005-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228365-A1 THIAZOLE DERIVATIVES AND USE THEREOF PF4, TEC, PDGFRB CYP1A2 2522/4885CYP3A4 1675/4885L3MBTL1 1332/4885
US-20090029998-A1 Thiazole Derivatives and Use Thereof PDGFRB, PDGFRA, TEC CYP1A2 2078/4885CYP3A4 1474/4885L3MBTL1 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.